We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds

By LabMedica International staff writers
Posted on 09 Feb 2024
Image: The researchers demonstrate how their sensor can detect fentanyl (Photo courtesy of University of Texas at Dallas)
Image: The researchers demonstrate how their sensor can detect fentanyl (Photo courtesy of University of Texas at Dallas)

Fentanyl, a synthetic opioid recognized by the Centers for Disease Control and Prevention as being 50 times more potent than heroin and 100 times more potent than morphine, is often illicitly combined with other drugs. Just 2 milligrams of fentanyl, roughly equivalent to 10 to 15 grains of table salt, can be fatal. Daily, over 150 people succumb to overdoses involving synthetic opioids such as fentanyl. Research has shown that fentanyl can be detected in urine up to 72 hours after use. Now, researchers have developed a first-of-its-kind, handheld device that is capable of accurately detecting fentanyl in urine within seconds.

The device developed by researchers at University of Texas at Dallas (Richardson, TX, USA) contains an electrochemical sensor that operates by generating electrical signals from chemical reactions. Detecting fentanyl was challenging due to its nonvolatile nature, meaning it doesn't naturally produce an electrochemical signature. To overcome this, the researchers designed a molecular cage-like structure resembling a mousetrap to capture fentanyl. This "trap" incorporates several components, including gold nanoparticles, and utilizes naloxone, a medication that reverses opioid overdoses, to attract and bind to fentanyl. When a urine sample is applied to a test strip, the presence of fentanyl triggers a reaction with the naloxone, resulting in a detectable signal.

This technology can also test other substances for fentanyl by simply diluting a sample in water and applying it to the sensor. The team's proof-of-concept device can detect trace amounts of fentanyl with 98% accuracy, bypassing the need for expensive and time-consuming lab analyses. The current prototype, designed for urine testing, is a precursor to developing a saliva-based test. Efforts are underway to expand the technology for detecting fentanyl in hair, with the ultimate goal being a saliva test. A saliva-based test would be particularly beneficial for first responders in making timely treatment decisions for overdose cases.

“There is an urgent demand for an easy-to-use, portable, miniaturized device that can detect fentanyl with high specificity and share results immediately to an internet-connected device,” said Dr. Shalini Prasad, professor and department head of bioengineering in the Erik Jonsson School of Engineering and Computer Science. “Our study demonstrates the feasibility of a highly accurate sensor to detect fentanyl within seconds.”

Related Links:
University of Texas at Dallas

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Automated Clinical Chemistry Analyzer
Envoy 500+

Channels

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more